A5019636254- Migraine and Headache Studies
- Traumatic Brain Injury Research
- Traumatic Brain Injury and Neurovascular Disturbances
- Psychosomatic Disorders and Their Treatments
- Cardiac Arrest and Resuscitation
- Neurological disorders and treatments
- Acute Ischemic Stroke Management
- Trigeminal Neuralgia and Treatments
- Sympathectomy and Hyperhidrosis Treatments
- Neurological Disorders and Treatments
- Parkinson's Disease Mechanisms and Treatments
- Cerebrovascular and Carotid Artery Diseases
- EEG and Brain-Computer Interfaces
- Palliative Care and End-of-Life Issues
- Ophthalmology and Eye Disorders
- Action Observation and Synchronization
- Antiplatelet Therapy and Cardiovascular Diseases
- Neuroscience and Neural Engineering
- Functional Brain Connectivity Studies
- Ethics in medical practice
- Advanced MRI Techniques and Applications
- Cardiovascular Syncope and Autonomic Disorders
- Long-Term Effects of COVID-19
- Stroke Rehabilitation and Recovery
- Botulinum Toxin and Related Neurological Disorders
University of L'Aquila
2016-2025
San Salvatore Hospital
2004-2025
Nuovo Ospedale San Giovanni di Dio
2024
The Neurological Institute
2023
John Wiley & Sons (United States)
2023
ASL Roma
2020
American Headache Society
2020
New York Proton Center
2020
Institute of Neurological Sciences
2019
Don Carlo Gnocchi Foundation
2016
Abstract Background We aimed to assess the efficacy and safety of erenumab, a fully human monoclonal antibody inhibiting calcitonin gene-related peptide receptor (CGRPr), for prevention migraine in real-life setting. Main body included our observational study all patients with episodic or chronic treated erenumab during year 2019 Abruzzo region, central Italy, 6-month follow-up. 89 patients; 76 (85.4%) received 6 doses 11 (12.4%) autonomously withdrew drug due perceived inefficacy, 2 (2.2%)...
To determine whether extending anti-CGRP mAb treatment beyond 3 years influences migraine course, we analyzed frequency during the first month of discontinuation following three 12-month cycles (Ts). This multicenter, prospective, real-world study enrolled 212 patients with high-frequency episodic (HFEM) or chronic (CM) who completed consecutive Ts subcutaneous mAbs. Discontinuation periods (D1, D2, D3) were defined as after T1, T2, and T3, respectively. The primary endpoint was ≥ 50%...
Background: Previous studies during SARS and Ebola pandemics have shown that quarantine is associated with several negative psychological effects, such as post-traumatic stress symptoms, confusion, anger. These conditions may affect the course of many diseases, including migraine. Although it possible measures for current COVID-19 pandemic migraine burden, no information currently available on this issue. Aim: In study, we aimed to: (1) explore changes in frequency, severity, days acute...
Triptans and erenumab are both migraine-specific agents acting on the calcitonin gene-related peptide pathway. Therefore, response to triptans might be associated with erenumab.In our study, consecutive patients referring Headache Centers of Abruzzo region from January 2019 March 2020 treated were interviewed about past use efficacy triptans. Triptan users classified as 'triptan responders' if they headache-free 2 h after treating ≥3 migraine attacks ≥1 triptan. We considered 'erenumab...
Abstract Background Monoclonal antibodies acting on the calcitonin gene-related peptide (CGRP) or its receptor have changed migraine preventive treatment. Those treatments led to reconsidering outcomes of prevention. Available data mostly considered benefits in terms relative efficacy (percent absolute decrease monthly days [MMDs] headache compared with baseline). However, not enough attention has been paid residual MMDs and/or migraine-related disability treated patients. In present study,...
Abstract Background It is well known that the course of migraine influenced by comorbidities and individual psychological characteristics may impact on disease. Proper identification factors are relevant to important improve non-pharmacological management. This study aimed at investigating relationship between in subjects free psychiatric comorbidities. Methods A sample women with episodic (EM) chronic (CM) without history were included this cross-sectional study. The also female healthy...
Randomized controlled trials (RCTs) proved that short-term (21-90 days) dual antiplatelet therapy (DAPT) reduces the risk of early ischemic recurrences after a noncardioembolic minor stroke or high-risk transient attack (TIA) without substantially increasing hemorrhagic risk. We aimed at understanding whether and how real-world use DAPT differs from RCTs.READAPT (Real-Life Study on Short-Term Dual Antiplatelet Treatment in Patients With Ischemic Stroke TIA) is prospective cohort study...
Background. Establishing prognosis in patients a persistent vegetative state (VS) is still challenging. Neural networks underlying consciousness may be regarded as complex systems whose outputs show degree of unpredictability experimentally quantifiable by means nonlinear parameters such approximate entropy (ApEn). Objective. The authors propose that the VS might result derangement above neural networks, with an ensuing decrease complexity and mutual interconnectivity: this lead to...